| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 40.72K | 63.64K | 433.29K | 222.61K | 314.79K | 722.74K | 255.4K | 226.21K | 464.28K | 705.92K |
| Revenue Growth % | 1.77% | 0.56% | 5.81% | -0.49% | 0.41% | 1.3% | -0.65% | -0.11% | 1.05% | 0.52% |
| Cost of Goods Sold | 46.23K | 31.24K | 27.49K | 416.64K | 245.47K | 175.35K | 208.68K | 172.25K | 80.97K | 118.57K |
| COGS % of Revenue | 1.14% | 0.49% | 0.06% | 1.87% | 0.78% | 0.24% | 0.82% | 0.76% | 0.17% | 0.17% |
| Gross Profit | -5.52K | 32.4K | 405.8K | -194.03K | 69.32K | 547.39K | 46.71K | 53.96K | 383.3K | 587.35K |
| Gross Margin % | -0.14% | 0.51% | 0.94% | -0.87% | 0.22% | 0.76% | 0.18% | 0.24% | 0.83% | 0.83% |
| Gross Profit Growth % | 0.64% | 6.87% | 11.52% | -1.48% | 1.36% | 6.9% | -0.91% | 0.16% | 6.1% | 0.53% |
| Operating Expenses | 1.25M | 1.96M | 7.02M | 3.95M | 4.2M | 6.07M | 6.55M | 6.59M | 6.08M | 12.22M |
| OpEx % of Revenue | 30.8% | 30.73% | 16.2% | 17.73% | 13.34% | 8.4% | 25.64% | 29.12% | 13.09% | 17.31% |
| Selling, General & Admin | 1.2M | 1.83M | 6.51M | 3.39M | 3.81M | 4.81M | 4.7M | 2.92M | 3.72M | 3.98M |
| SG&A % of Revenue | 29.4% | 28.8% | 15.03% | 15.21% | 12.11% | 6.65% | 18.42% | 12.91% | 8.01% | 5.64% |
| Research & Development | 9.02K | 54.19K | 492.86K | 555.73K | 387.07K | 1.26M | 1.84M | 3.67M | 2.36M | 8.24M |
| R&D % of Revenue | 0.22% | 0.85% | 1.14% | 2.5% | 1.23% | 1.75% | 7.21% | 16.21% | 5.08% | 11.67% |
| Other Operating Expenses | -48.02K | -68.61K | -12.97K | -7.18K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.26M | -1.92M | -6.61M | -4.14M | -4.13M | -5.52M | -6.5M | -6.53M | -5.7M | -11.63M |
| Operating Margin % | -30.94% | -30.22% | -15.26% | -18.61% | -13.12% | -7.64% | -25.45% | -28.89% | -12.27% | -16.48% |
| Operating Income Growth % | 0.35% | -0.53% | -2.44% | 0.37% | 0% | -0.34% | -0.18% | -0.01% | 0.13% | -1.04% |
| EBITDA | -1.26M | -1.92M | -6.61M | -4.08M | -3.98M | -5.37M | -6.35M | -6.39M | -5.62M | -11.52M |
| EBITDA Margin % | -30.92% | -30.2% | -15.26% | -18.33% | -12.65% | -7.43% | -24.88% | -28.24% | -12.1% | -16.32% |
| EBITDA Growth % | 0.35% | -0.53% | -2.44% | 0.38% | 0.02% | -0.35% | -0.18% | -0.01% | 0.12% | -1.05% |
| D&A (Non-Cash Add-back) | 619 | 1.49K | 2.31K | 60.55K | 146.09K | 147.6K | 146.91K | 145.4K | 76.15K | 115.85K |
| EBIT | -1.26M | -1.92M | -6.61M | -4.16M | -4.15M | -4.16M | -7.38M | -6.71M | -5.81M | -11.91M |
| Net Interest Income | -2.25K | -6.01K | 0 | 0 | 0 | 0 | 0 | 43.19K | 14.31K | 3.02K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 43.19K | 14.31K | 3.02K |
| Interest Expense | 2.25K | 6.01K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -17.63K | -6.01K | 4K | -16.43K | -19.89K | 1.36M | -882.81K | -178.5K | -113.36K | -278.06K |
| Pretax Income | -1.28M | -1.93M | -6.61M | -4.16M | -4.15M | -4.16M | -7.38M | -6.71M | -5.81M | -11.91M |
| Pretax Margin % | -31.37% | -30.32% | -15.25% | -18.68% | -13.18% | -5.76% | -28.91% | -29.67% | -12.51% | -16.87% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.95% | 0.97% | 1% | 0.99% | 0.95% | 0.97% | 0.98% | 0.99% | 1% | 1% |
| Net Income | -1.21M | -1.87M | -6.6M | -4.1M | -3.93M | -4.03M | -7.27M | -6.66M | -5.8M | -11.9M |
| Net Margin % | -29.83% | -29.37% | -15.23% | -18.42% | -12.5% | -5.57% | -28.46% | -29.46% | -12.48% | -16.86% |
| Net Income Growth % | 0.31% | -0.54% | -2.53% | 0.38% | 0.04% | -0.02% | -0.81% | 0.08% | 0.13% | -1.05% |
| Net Income (Continuing) | -1.28M | -1.93M | -6.61M | -4.16M | -4.15M | -4.16M | -7.38M | -6.71M | -5.81M | -11.91M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 64.18K | -22K | 0 | 0 | 0 | 0 |
| Minority Interest | -178.29K | -238.48K | 0 | 107.67K | -42.94K | -202.09K | -316.41K | -364.04K | -377.35K | -386.94K |
| EPS (Diluted) | -0.83 | -0.95 | -2.79 | -1.62 | -1.42 | -0.92 | -1.24 | -1.01 | -0.47 | -0.66 |
| EPS Growth % | 0.38% | -0.14% | -1.94% | 0.42% | 0.12% | 0.35% | -0.35% | 0.19% | 0.53% | -0.4% |
| EPS (Basic) | -0.83 | -0.95 | -2.79 | -1.62 | -1.42 | -0.92 | -1.24 | -1.01 | -0.47 | -0.66 |
| Diluted Shares Outstanding | 1.46M | 1.96M | 2.37M | 2.59M | 2.77M | 4.39M | 5.89M | 6.61M | 12.38M | 18M |
| Basic Shares Outstanding | 1.46M | 1.96M | 2.37M | 2.59M | 2.77M | 4.39M | 5.89M | 6.61M | 12.38M | 18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 510.17K | 2.8M | 2.28M | 1.82M | 1.93M | 12.44M | 6.98M | 2.2M | 7.9M | 3.47M |
| Cash & Short-Term Investments | 93.41K | 2.53M | 1.74M | 1.35M | 1.31M | 11.75M | 6.16M | 1.48M | 6.56M | 1.97M |
| Cash Only | 93.41K | 2.53M | 1.73M | 1.29M | 1.29M | 10.92M | 5.81M | 1.35M | 6.5M | 1.8M |
| Short-Term Investments | 0 | 0 | 10.15K | 64.21K | 19.32K | 833.84K | 347.33K | 125.64K | 55.81K | 165.36K |
| Accounts Receivable | 131.08K | 45.29K | 265.75K | 273.14K | 313.93K | 342.4K | 201.78K | 175.25K | 154.48K | 368.36K |
| Days Sales Outstanding | 1.18K | 259.78 | 223.87 | 447.86 | 363.99 | 172.92 | 288.38 | 282.77 | 121.44 | 190.46 |
| Inventory | 134.72K | 67.17K | 87.23K | 127.4K | 116.87K | 29.65K | 38.42K | 0 | 0 | 0 |
| Days Inventory Outstanding | 1.06K | 784.89 | 1.16K | 111.61 | 173.78 | 61.72 | 67.2 | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 56.47K | 64.68K | 147.78K | 856.39K | 902.28K | 823.88K | 856.41K | 884.21K | 969.8K | 706.78K |
| Property, Plant & Equipment | 2.48K | 1.86K | 1.24K | 591.26K | 610.28K | 459.25K | 367.95K | 421.59K | 389.55K | 334.94K |
| Fixed Asset Turnover | 16.45x | 34.29x | 350.27x | 0.38x | 0.52x | 1.57x | 0.69x | 0.54x | 1.19x | 2.11x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 54K | 62.83K | 146.54K | 265.13K | 292K | 364.62K | 488.46K | 462.63K | 516.68K | 307.82K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 63.58K | 64.01K |
| Total Assets | 566.64K | 2.86M | 2.43M | 2.68M | 2.83M | 13.27M | 7.83M | 3.08M | 8.87M | 4.18M |
| Asset Turnover | 0.07x | 0.02x | 0.18x | 0.08x | 0.11x | 0.05x | 0.03x | 0.07x | 0.05x | 0.17x |
| Asset Growth % | -0.2% | 4.05% | -0.15% | 0.1% | 0.06% | 3.69% | -0.41% | -0.61% | 1.88% | -0.53% |
| Total Current Liabilities | 433.88K | 92.35K | 43.64K | 184.51K | 225.92K | 153.28K | 194.04K | 267.74K | 1.1M | 1.49M |
| Accounts Payable | 90.01K | 32.57K | 14.38K | 31.46K | 45.08K | 104.89K | 120.15K | 225.04K | 1.06M | 1.37M |
| Days Payables Outstanding | 710.6 | 380.61 | 190.89 | 27.56 | 67.03 | 218.34 | 210.14 | 476.87 | 4.77K | 4.2K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 7.93K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 12.5K | 17.08K | 0 | 0 | 44.26K | 0 | 0 | 0 | 4.96K | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 1.18x | 30.27x | 52.34x | 9.86x | 8.53x | 81.18x | 35.96x | 8.22x | 7.18x | 2.32x |
| Quick Ratio | 0.87x | 29.54x | 50.34x | 9.17x | 8.01x | 80.99x | 35.76x | 8.22x | 7.18x | 2.32x |
| Cash Conversion Cycle | 1.53K | 664.06 | 1.19K | 531.9 | 470.74 | 16.3 | 145.43 | - | - | - |
| Total Non-Current Liabilities | 45K | 0 | 0 | 0 | 120.06K | 49.99K | 7.4K | 136.17K | 109.32K | 78.9K |
| Long-Term Debt | 45K | 0 | 0 | 0 | 30.67K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 89.39K | 49.99K | 7.4K | 136.17K | 109.32K | 78.9K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 478.88K | 92.35K | 43.64K | 184.51K | 345.98K | 203.26K | 201.44K | 403.91K | 1.21M | 1.57M |
| Total Debt | 45K | 42.69K | 7.86K | 0 | 156.1K | 97.32K | 49.99K | 163.97K | 137.37K | 109.32K |
| Net Debt | -48.41K | -2.49M | -1.72M | -1.29M | -1.14M | -10.82M | -5.76M | -1.19M | -6.36M | -1.69M |
| Debt / Equity | 0.51x | 0.02x | 0.00x | - | 0.06x | 0.01x | 0.01x | 0.06x | 0.02x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -559.83x | -319.78x | - | - | - | - | - | - | - | - |
| Total Equity | 87.76K | 2.77M | 2.39M | 2.49M | 2.48M | 13.06M | 7.63M | 2.68M | 7.66M | 2.6M |
| Equity Growth % | -0.87% | 30.54% | -0.14% | 0.04% | -0% | 4.26% | -0.42% | -0.65% | 1.86% | -0.66% |
| Book Value per Share | 0.06 | 1.41 | 1.01 | 0.96 | 0.90 | 2.97 | 1.30 | 0.41 | 0.62 | 0.14 |
| Total Shareholders' Equity | 266.05K | 3.01M | 2.39M | 2.38M | 2.53M | 13.27M | 7.95M | 3.04M | 8.04M | 2.99M |
| Common Stock | 51.29K | 67.98K | 75.53K | 78.79K | 3K | 5.73K | 5.95K | 8.09K | 15.81K | 19.56K |
| Retained Earnings | -11.3M | -13.17M | -19.77M | -23.87M | -27.8M | -31.83M | -39.1M | -45.76M | -51.56M | -63.46M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -14.25K | 0 | 0 | 0 | 0 | 0 | -19.82K | -70.33K |
| Minority Interest | -178.29K | -238.48K | 0 | 107.67K | -42.94K | -202.09K | -316.41K | -364.04K | -377.35K | -386.94K |
| Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -660.86K | -1.55M | -2.52M | -3.01M | -2.62M | -3.99M | -4.88M | -5.88M | -4.96M | -10.45M |
| Operating CF Margin % | -16.23% | -24.29% | -5.81% | -13.5% | -8.32% | -5.52% | -19.1% | -26% | -10.68% | -14.8% |
| Operating CF Growth % | 0.56% | -1.34% | -0.63% | -0.19% | 0.13% | -0.52% | -0.22% | -0.21% | 0.16% | -1.11% |
| Net Income | -1.28M | -1.93M | -6.61M | -4.16M | -4.08M | -4.19M | -7.38M | -6.71M | -5.81M | -11.91M |
| Depreciation & Amortization | 619 | 1.49K | 2.31K | 60.55K | 146.09K | 147.6K | 102.72K | 145.4K | 76.15K | 87.83K |
| Stock-Based Compensation | 122.02K | 113.04K | 2.6M | 626.69K | 1.14M | 410.01K | 752.59K | 170.38K | 492.24K | 859.49K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 155.79K | 570.15K | 1.86M | 385.93K | 374.83K | -424.66K | 2M | 372.25K | 174.71K | 318.15K |
| Working Capital Changes | 337.97K | -301.12K | -371.23K | 79.68K | -194.36K | 63.53K | -351.48K | 143.26K | 106.56K | 195.58K |
| Change in Receivables | -6.2K | -7.71K | -245.46K | -138.64K | -90.78K | 189.58K | -137.49K | 26.54K | -50.57K | -214.32K |
| Change in Inventory | -10.78K | -1.06K | -33.02K | -47.34K | 4.21K | 95.04K | -1.98K | 43.07K | 0 | 0 |
| Change in Payables | 56.94K | -40.44K | 3.21K | 100.63K | -49.49K | 13.8K | 50.73K | 88.49K | 826.47K | 0 |
| Cash from Investing | -20.1K | -9.7K | -155.4K | -769.16K | -26.84K | 193.88K | -180.64K | -169.61K | -188.6K | -243.02K |
| Capital Expenditures | -3.09K | -9.7K | -85.4K | -646.18K | -33.65K | -79.49K | -49.19K | -33.75K | -43.01K | -24.65K |
| CapEx % of Revenue | 0.08% | 0.15% | 0.2% | 2.9% | 0.11% | 0.11% | 0.19% | 0.15% | 0.09% | 0.03% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -17.01K | 0 | 0 | -122.98K | 0 | 273.37K | -131.45K | -135.86K | -145.59K | -218.37K |
| Cash from Financing | 514.29K | 4M | 1.87M | 3.33M | 2.65M | 13.42M | -44.6K | 1.59M | 10.32M | 6.05M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 0 | 1M | 0 | 4.02M | 0 | 0 | 6.11M | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -680.96K | -1.56M | -2.6M | -3.77M | -2.65M | -4.07M | -4.93M | -6.05M | -5M | -10.48M |
| FCF Margin % | -16.72% | -24.44% | -6.01% | -16.96% | -8.43% | -5.63% | -19.3% | -26.75% | -10.77% | -14.84% |
| FCF Growth % | 0.56% | -1.28% | -0.67% | -0.45% | 0.3% | -0.53% | -0.21% | -0.23% | 0.17% | -1.09% |
| FCF per Share | -0.47 | -0.79 | -1.10 | -1.46 | -0.96 | -0.93 | -0.84 | -0.91 | -0.40 | -0.58 |
| FCF Conversion (FCF/Net Income) | 0.54x | 0.83x | 0.38x | 0.73x | 0.67x | 0.99x | 0.67x | 0.88x | 0.86x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 13.92K | 12.98K | 16.3K | 4.78K | 8.21K | 10.04K | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -326.4% | -130.92% | -255.97% | -168.05% | -158.22% | -51.81% | -70.25% | -129.26% | -112.11% | -231.96% |
| Return on Invested Capital (ROIC) | -433.48% | -911.5% | -1048.56% | -331.46% | -242.86% | -230.81% | -237.12% | -291.59% | -306.37% | -790.85% |
| Gross Margin | -13.55% | 50.91% | 93.66% | -87.16% | 22.02% | 75.74% | 18.29% | 23.86% | 82.56% | 83.2% |
| Net Margin | -2983.38% | -2937.31% | -1522.97% | -1841.53% | -1249.71% | -557.19% | -2846.3% | -2946.36% | -1248.25% | -1686% |
| Debt / Equity | 0.51x | 0.02x | 0.00x | - | 0.06x | 0.01x | 0.01x | 0.06x | 0.02x | 0.04x |
| Interest Coverage | -559.83x | -319.78x | - | - | - | - | - | - | - | - |
| FCF Conversion | 0.54x | 0.83x | 0.38x | 0.73x | 0.67x | 0.99x | 0.67x | 0.88x | 0.86x | 0.88x |
| Revenue Growth | 176.96% | 56.29% | 580.85% | -48.62% | 41.41% | 129.59% | -64.66% | -11.43% | 105.24% | 52.05% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| IP Licensing | - | - | - | - | - | 146.8K | 457.99K | 696K |
| IP Licensing Growth | - | - | - | - | - | - | 211.98% | 51.97% |
| B2B | - | - | - | 383.18K | - | - | - | 9.92K |
| B2B Growth | - | - | - | - | - | - | - | - |
| Other | - | - | - | - | - | 35.24K | 900 | - |
| Other Growth | - | - | - | - | - | - | -97.45% | - |
| Research & Development | - | - | - | - | 54.8K | - | - | - |
| Research & Development Growth | - | - | - | - | - | - | - | - |
| Licensing Revenue | - | - | - | 334.97K | 54.56K | - | - | - |
| Licensing Revenue Growth | - | - | - | - | -83.71% | - | - | - |
| Other Revenue | - | - | - | 4.58K | 32.6K | - | - | - |
| Other Revenue Growth | - | - | - | - | 610.99% | - | - | - |
| License | 415.18K | 198K | 232.91K | - | - | - | - | - |
| License Growth | - | -52.31% | 17.63% | - | - | - | - | - |
| Product | 16.97K | 24.28K | 150.99K | - | - | - | - | - |
| Product Growth | - | 43.11% | 521.83% | - | - | - | - | - |
| Freight revenuet | - | 328 | 641 | - | - | - | - | - |
| Freight revenuet Growth | - | - | 95.43% | - | - | - | - | - |
| Cargo and Freight | 1.14K | - | - | - | - | - | - | - |
| Cargo and Freight Growth | - | - | - | - | - | - | - | - |
Lexaria Bioscience Corp. (LEXX) reported $0.5M in revenue for fiscal year 2025. This represents a 62% decrease from $1.4M in 2012.
Lexaria Bioscience Corp. (LEXX) grew revenue by 52.0% over the past year. This is strong growth.
Lexaria Bioscience Corp. (LEXX) reported a net loss of $10.8M for fiscal year 2025.
Lexaria Bioscience Corp. (LEXX) has a return on equity (ROE) of -232.0%. Negative ROE indicates the company is unprofitable.
Lexaria Bioscience Corp. (LEXX) had negative free cash flow of $8.7M in fiscal year 2025, likely due to heavy capital investments.